Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Optinose Inc (NQ: OPTN )

1.250 +0.020 (+1.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 168,858
Open 1.210
Bid (Size) 1.210 (85)
Ask (Size) 1.290 (5)
Prev. Close 1.230
Today's Range 1.210 - 1.290
52wk Range 0.9000 - 3.739
Shares Outstanding 53,309,012
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Optinose to Present at the 2023 Cantor Global Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023
Via Benzinga

Performance

YTD
-31.69%
-31.69%
1 Month
N/A
N/A
3 Month
+0.81%
+0.81%
6 Month
-36.22%
-36.22%
1 Year
-64.39%
-64.39%

More News

Read More
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Recap: OptiNose Q1 Earnings
Via Benzinga
OptiNose's Return On Capital Employed Insights
Via Benzinga
Earnings Preview: OptiNose
Via Benzinga
Earnings Scheduled For August 10, 2023
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Optinose, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Optinose to Present at the Jefferies Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the Needham Virtual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces CEO Transition and Business Update
From Optinose, Inc.
Via GlobeNewswire
Optinose Appoints Paul Spence as Chief Commercial Officer
From Optinose, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.